Ausgabe 3/2021
Inhalt (23 Artikel)
Application of Telemedicine in Diabetes Care: The Time is Now
Felix Aberer, Daniel A. Hochfellner, Julia K. Mader
What’s in a Name? Redefining Type 2 Diabetes Remission
Sanjay Kalra, Arbinder Singal, Tejal Lathia
Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study
Yuta Yoshizawa, Michihiro Hosojima, Hideyuki Kabasawa, Naohito Tanabe, Daisuke Ugamura, Yutaka Koda, Hisaki Shimada, Tetsuya Takasawa, Takahito Ito, Tadahiro Kitamura, Masaki Kobayashi, Yoshiki Suzuki, Ichiei Narita, Akihiko Saito
Skin Autofluorescence in Young Adult Offspring of Women with Type 1 Diabetes: A Cross-Sectional Case–Control Study
Cedric Korpijaakko, Niko Wasenius, Kari Teramo, Miira M. Klemetti, Hannu Kautiainen, Johan G. Eriksson, Merja K. Laine
The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from India
Sanjay Kalra, A. G. Unnikrishnan, Ganapathi Bantwal, Sambit Das, Nareen Krishna Polavarapu, Kumar Gaurav
Risk Factors for Albuminuria in Normotensive Older Adults with Type 2 Diabetes Mellitus and Normal Renal Function: A Cross-Sectional Study
Yingyi Zhou, Ke Chen, Xuan Du, Jiali Tang, Bimin Shi
Movement is Improvement: The Therapeutic Effects of Exercise and General Physical Activity on Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Sayed Z. A. Shah, Jawad A. Karam, Alam Zeb, Rafi Ullah, Arif Shah, Ijaz Ul Haq, Iftikhar Ali, Haider Darain, Hong Chen
Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study
Martin Pfohl, Jochen Seufert, Anja Borck, Peter Bramlage, Thorsten Siegmund
Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study
Jochen Seufert, Martin Pfohl, Anja Borck, Peter Bramlage, Thorsten Siegmund
Impact of Intensive Glucose Control on Brain Health: Meta-Analysis of Cumulative Data from 16,584 Patients with Type 2 Diabetes Mellitus
Xingyao Tang, Marly A. Cardoso, Jinkui Yang, Jian-Bo Zhou, Rafael Simó
Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
Gian Paolo Fadini, Olga Disoteo, Riccardo Candido, Paolo Di Bartolo, Luigi Laviola, Agostino Consoli
Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study
David M. Williams, Aliya M. Ruslan, Rahim Khan, Daneeshanan Vijayasingam, Fizzah Iqbal, Ayesha Shaikh, Jia Lim, Richard Chudleigh, Rajesh Peter, Maneesh Udiawar, Stephen C. Bain, Jeffrey W. Stephens, Thinzar Min
Injection Technique Education in Patients with Diabetes Injecting Insulin into Areas of Lipohypertrophy: A Randomized Controlled Trial
Liming Chen, Qiuling Xing, Jing Li, Jianxin Zhou, Yi Yuan, Ying Wan, Brian K. Pflug, Kenneth W. Strauss, Laurence J. Hirsch
Glucose Variability is Independently Correlated with Serum Level of Pigment Epithelium-Derived Factor in Type 2 Diabetes
Tomoki Fujikawa, Makoto Ohara, Yo Kohata, Hiroe Nagaike, Ayako Fukase, Naoya Osaka, Hironori Yashima, Nobuko Sato, Hideki Kushima, Kyoko Shinmura, Yasuyoshi Takahashi, Munenori Hiromura, Michishige Terasaki, Yusaku Mori, Tomoyasu Fukui, Takanori Matsui, Tsutomu Hirano, Sho-ichi Yamagishi
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Haleh Chehrehgosha, Masoud Reza Sohrabi, Faramarz Ismail-Beigi, Mojtaba Malek, Mohammad Reza Babaei, Farhad Zamani, Hossein Ajdarkosh, Mahmood Khoonsari, Afshin Eshghi Fallah, Mohammad E. Khamseh
Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
Hiroaki Seino
Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
Ildiko Lingvay, Andreas R. Kirk, Søren Lophaven, Michael L. Wolden, Jay H. Shubrook
Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes
Yoshio Nagai, Kiyoyasu Kazumori, Tomomi Takeshima, Kosuke Iwasaki, Yasushi Tanaka
Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Patients with T2D Uncontrolled on NPH or Premixed Insulins as Part of Routine Clinical Practice in Bulgaria: ToUPGRADE Study
Zdravko Kamenov, Veselina Pehlivanova, Tsvetodara Kuneva, Kiril Kirilov, Roza Bobeva, Julija Stoykova, Svetla Mihalevska
A Pragmatic Study of Basal and Mid-Mixture Insulins as Starter Insulins in Chinese Patients With Type 2 Diabetes: Observations From Long-Term, Real-World Experience
Tianshu Zeng, Huijuan Yuan, Jiangong Ren, Yuanyuan Li, Jianing Hou, Liying Du, Jiankun Zhu, Lulu Chen, Linong Ji
Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study
Matthias Hepprich, Daniela Zillig, Manuel A. Florian-Reynoso, Marc Y. Donath, Gottfried Rudofsky
Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)
Hiroshi Nomoto, Chiho Oba-Yamamoto, Yuka Takahashi, Jun Takeuchi, So Nagai, Hiroki Yokoyama, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Hiraku Kameda, Kyu Yong Cho, Akinobu Nakamura, Tatsuya Atsumi, Hideaki Miyoshi